# eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

> **NCT05753735** · PHASE2 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Pancreatic Fistula

## Interventions

- **DRUG:** Piperacillin/Tazobactam
- **DRUG:** Amoxicillin/ Clavulanic acid

## Key facts

- **NCT ID:** NCT05753735
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-18
- **Primary completion:** 2024-03-14
- **Final completion:** 2024-06-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Principal investigator left the institution.
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753735, "eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05753735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*